SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications of cancer in the United States. The company is headquartered in New York, New York.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 900,000 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -43.60% |
| Return on Assets | -25.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.59 |
| Price-to-Book | 27.41 |
| Price-to-Sales (TTM) | 26.90 |
| EV/Revenue | 20.84 |
| EV/EBITDA | -1.71 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -82.50% |
| Shares Outstanding | $196.63M |
| Float | $185.23M |
| % Insiders | 0.95% |
| % Institutions | 27.80% |
Volatility is currently expanding
Sellas Life Sciences (SLS) shares are extending gains on Jun. 26 following a key regulatory filing that disclosed a series of comprehensive corporate amendments regarding executive compensation and protection. Specifically, the board restructured change-of-control and severance agreements for CEO Angelos Stergiou, CFO John Burns, and CDO Dragan Cicic.
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will participate in the following upcoming investor conferences: 2026 Stifel Virtual Targeted Oncology Forum Format: Corporate Presentation and Fireside Chat Date and Time: Tuesday, May 19, 2026, at 2:00 PM ET Location: New York, NY Webcast Link: Click here A.G.P.
– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS Remains Blinded to Trial Outcomes – – Final Analysis of REGAL Trial of GPS in AML to be Conducted Following the 80 th Event – – Ongoing Dosing of Patients in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML – – $107.1 Million in Cash and Cash Equivalents as of March 31, 2026; Additional $7.5 Million in Proceeds Received in Q2 2026 to Date through Warrant Exercises – NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. “The first quarter of 2026 marked an important period for SELLAS as we continued to execute across our clinical programs while preparing for the anticipated pivotal Phase 3 REGAL trial data readout,” said Angelos Stergiou, MD, ScD h.c.
SELLAS Life Sciences is rated 'Hold' due to pending phase 3 REGAL data for GPS in AML after CR2, a major 2026 catalyst. The company's GPS targets WT1 in AML, with prior phase 1/2 data showing a median OS of 21 months versus 5.4 months for standard therapy. Interim REGAL analysis showed fewer than 50% deceased at 13.5 months; final analysis at 80 events expected in 1H 2026.
The mean of analysts' price targets for SELLAS Life Sciences Group, Inc. (SLS) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The consensus price target hints at a 63.6% upside potential for SELLAS Life Sciences Group, Inc. (SLS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
